Literature DB >> 9696861

Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1.

K E Follis1, M Trahey, R A LaCasse, J H Nunberg.   

Abstract

The differential use of CC chemokine receptor 5 (CCR5) and CXC chemokine receptor 4 (CXCR4) may be intimately involved in the transmission and progression of human immunodeficiency virus infection. Changes in coreceptor utilization have also been noted upon adaptation of primary isolates (PI) to growth in established T-cell lines. All of the T-cell line-adapted (TCLA) viruses studied to date utilize CXCR4 but not CCR5. This observation had been suggested as an explanation for the sensitivity of TCLA, but not PI, viruses to neutralization by recombinant gp120 antisera and V3-directed monoclonal antibodies, but recent studies have shown coreceptor utilization to be independent of neutralization sensitivity. Here we describe a newly isolated TCLA virus that is sensitive to neutralization but continues to utilize both CXCR4 and CCR5 for infection. This finding further divorces coreceptor specificity from neutralization sensitivity and from certain changes in cell tropism. That the TCLA virus can continue to utilize CCR5 despite the changes that occur upon adaptation and in the apparent absence of CCR5 expression in the FDA/H9 T-cell line suggests that the interaction between envelope protein and coreceptor may be mediated by multiple weak interactions along a diffuse surface.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696861      PMCID: PMC110016     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

2.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

3.  The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.

Authors:  H Choe; M Farzan; Y Sun; N Sullivan; B Rollins; P D Ponath; L Wu; C R Mackay; G LaRosa; W Newman; N Gerard; C Gerard; J Sodroski
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

4.  Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.

Authors:  F Gao; S G Morrison; D L Robertson; C L Thornton; S Craig; G Karlsson; J Sodroski; M Morgado; B Galvao-Castro; H von Briesen; S Beddows; J Weber; P M Sharp; G M Shaw; B H Hahn
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

5.  Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual.

Authors:  M Groenink; R A Fouchier; R E de Goede; F de Wolf; R A Gruters; H T Cuypers; H G Huisman; M Tersmette
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

6.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.

Authors:  R A Fouchier; M Groenink; N A Kootstra; M Tersmette; H G Huisman; F Miedema; H Schuitemaker
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

7.  HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay.

Authors:  M Koot; A H Vos; R P Keet; R E de Goede; M W Dercksen; F G Terpstra; R A Coutinho; F Miedema; M Tersmette
Journal:  AIDS       Date:  1992-01       Impact factor: 4.177

8.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Authors:  J R Mascola; S W Snyder; O S Weislow; S M Belay; R B Belshe; D H Schwartz; M L Clements; R Dolin; B S Graham; G J Gorse; M C Keefer; M J McElrath; M C Walker; K F Wagner; J G McNeil; F E McCutchan; D S Burke
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

10.  Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1.

Authors:  P Lusso; F Cocchi; C Balotta; P D Markham; A Louie; P Farci; R Pal; R C Gallo; M S Reitz
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more
  3 in total

1.  Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.

Authors:  Junji Shibata; Kazuhisa Yoshimura; Akiko Honda; Atsushi Koito; Toshio Murakami; Shuzo Matsushita
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

2.  Characterization of SIV in the oral cavity and in vitro inhibition of SIV by rhesus macaque saliva.

Authors:  Jessica S Thomas; Nedra Lacour; Pamela A Kozlowski; Steve Nelson; Gregory J Bagby; Angela M Amedee
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08       Impact factor: 2.205

3.  Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1.

Authors:  J York; K E Follis; M Trahey; P N Nyambi; S Zolla-Pazner; J H Nunberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.